Saturday 17 October 2026 Export DYAI’s income statement to Excel — free account

Dyadic International Inc.

Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat, free cash flow fell 1,298.5% and total debt was flat, each against the same quarter a year earlier.

0.41 0.01 −2.38%

Follow DYAI

Alert me

Market cap: $16.8M
P/E: 0.0×
Fwd P/E: −7.4×
Dividend yield: —
F-score: 2/9
Altman Z: −12.37
Beneish M: 1.00
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.12

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	1	—	—	—

Insider Ownership 15.37%

Capital & Financial Ratios $m

Market Cap 16.80

Revenue 3.80

Net Income (7.62)

Free Cash Flow (7.40)

Net Debt 0.37

Current Ratio 1.65

Debt/Equity (2.11)

P/E ratio 0.00

Fwd P/E (7.35)

P/S ratio 3.93

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 39.13%

Next Y EPS Growth 121.43%

Next Y revenue growth 113.18%

Next 5Y EPS Growth 64.84%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.24%

10-year low 10-year high

EV/Sales against its own 10 years 2.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	7	9	9	5
Receivables	0	0	1	1
Inventory	—	—	—	—
Other	—	—	—	—
	8	10	10	6

	2023	2024	2025	Q'26
Payables	1	0	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	2	4	4

Compound Annual Growth %

	10y	5y	3y
Sales	25.61%	14.04%	1.79%
Cash Flow	—	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	—	(46.62%)	(51.92%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	0	1	1	1	3
’24	0	0	2	1	3
’23	1	1	0	1	3
’22	1	1	1	1	3
’21	0	1	1	0	2
’20	0	1	0	0	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	0	(2)	(2)	(6)
’24	(1)	(2)	0	(1)	(4)
’23	(2)	(2)	(2)	(1)	(7)
’22	(3)	(2)	(2)	(2)	(8)
’21	(2)	(2)	(4)	(3)	(11)
’20	(2)	(2)	(1)	(1)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	0	(2)	(2)	(6)
’24	(1)	(2)	0	(1)	(4)
’23	(2)	(2)	(2)	(1)	(7)
’22	(3)	(2)	(2)	(2)	(8)
’21	(2)	(2)	(4)	(3)	(11)
’20	(2)	(2)	(1)	(1)	(7)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	(0.06)	—	—	—
’25	(0.07)	(0.06)	(0.06)	(0.06)	(0.23)
’24	(0.07)	(0.07)	(0.01)	(0.05)	(0.20)
’23	(0.03)	(0.07)	(0.06)	(0.08)	(0.24)
’22	(0.09)	(0.12)	(0.06)	(0.07)	(0.34)
’21	(0.12)	(0.14)	(0.06)	(0.15)	(0.47)
’20	(0.08)	(0.10)	(0.09)	(0.07)	(0.34)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.32	1.23	1.38	1.77	2.51	3.15	1.12	1.20	0.93	0.71	Analyst estimates 2026–2028 Powerpack
	High	1.85	1.81	2.29	7.30	10.98	8.78	4.98	2.40	2.67	2.14
People
People	Employees	—	—	6	6	6	7	7	7	6	5
	Revenue/emp, $m	0.00	0.00	0.22	0.28	0.27	0.34	0.42	0.41	0.58	0.62
Income, $m
Income, $m	Revenue	1	1	1	2	2	2	3	3	3	3
	Gross margin, %	100.00	10.31	20.70	13.17	11.05	19.11	27.54	31.84	65.82	24.93
	EBT	1	(2)	(7)	(8)	(9)	(13)	(10)	(7)	(6)	(7)
	EBT margin, %	100.00	(290.41)	(517.01)	(493.59)	(580.19)	(543.73)	(332.23)	(234.42)	(166.20)	(238.31)
	Net income	0	(2)	(6)	(8)	(9)	(13)	(10)	(7)	(6)	(7)
	Depreciation	—	1	1	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.02	0.03	0.05	0.06	0.06	0.09	0.10	0.10	0.12	0.09
	Earnings	(0.10)	(0.07)	(0.21)	(0.31)	(0.34)	(0.47)	(0.34)	(0.24)	(0.20)	(0.23)
	Cash flow	(0.17)	(0.06)	(0.16)	(0.21)	(0.24)	(0.41)	(0.28)	(0.23)	(0.14)	(0.17)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.17)	(0.06)	(0.16)	(0.21)	(0.24)	(0.41)	(0.28)	(0.23)	(0.14)	(0.17)
	Book value	1.58	1.73	1.53	1.33	1.04	0.66	0.39	0.20	0.08	0.04
	Shares, m	37	29	28	27	27	28	28	29	29	33
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	63.08	40.39	83.21	92.26	52.35	13.36	15.80	14.68	9.92
	P/B	0.00	0.96	1.23	3.90	5.20	6.84	3.53	7.79	20.77	24.88
	EV/Sales	(8.35)	0.25	8.57	62.85	74.10	43.92	9.04	13.33	13.45	8.78
	EV/FCF	0.00	(0.15)	(2.46)	(17.93)	(17.76)	(9.27)	(3.23)	(5.65)	(11.51)	(4.67)
Cash, $m
Cash, $m	Operating cash flow	(6)	(2)	(4)	(6)	(7)	(11)	(8)	(7)	(4)	(6)
	Capex	—	—	—	—	—	—	—	—	—	—
	Free cash flow	(6)	(2)	(4)	(6)	(7)	(11)	(8)	(7)	(4)	(6)
Balance, $m
Balance, $m	Working capital	57	49	42	34	28	18	11	6	7	6
	Total debt	—	—	—	—	—	—	—	—	5	5
	Net debt	(56)	(48)	(41)	(34)	(29)	(20)	(13)	(7)	(4)	(4)
	Shareholders’ equity	58	50	42	36	28	18	11	6	2	1
Returns, %
Returns, %	ROA	0.00	(8.42)	(12.10)	(20.58)	(27.62)	(50.89)	(55.61)	(61.97)	(64.01)	(74.11)
	ROIC	26.74	20.70	(380.11)	(353.37)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(12.14)	(3.97)	(12.32)	(21.22)	(29.00)	(55.81)	(66.05)	(80.11)	(139.16)	(397.80)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ATYR aTyr Pharma, Inc.	$18.0M	— (loss-making)	— (loss-making)	−90.75% (below 0%: shrinking)	n/m	+32.22% (above 0%: growing)	100.00%	0.00%	Compare
NEUP Neuphoria Therapeutics Inc.	$17.9M	— (loss-making)	— (loss-making)	−107.32% (below 0%: shrinking)	n/m	+133.86% (above 0%: growing)	100.00%	0.00%	Compare
JSPR Jasper Therapeutics, Inc.	$17.7M	— (loss-making)	—	—	n/m	+55.74% (above 0%: growing)	0.00%	0.00%	Compare
ANEB Anebulo Pharmaceuticals, Inc.	$17.6M	— (loss-making)	—	—	n/m	+6.58% (above 0%: growing)	—	0.00%	Compare
ACGN Aceragen, Inc.	$17.1M	— (loss-making)	— (loss-making)	+2,394.95% (above 0%: growing)	n/m	−115.67% (below 0%: shrinking)	100.00%	(834.33%)	Compare
RADX Radiopharm Theranostics Limited - Sponsored ADR	$17.0M	—	—	—	—	−137.75% (below 0%: shrinking)	—	—	Compare
DYAI Dyadic International Inc.	$16.8M	— (loss-making)	— (loss-making)	−0.57% (below 0%: shrinking)	n/m	−1,298.54% (below 0%: shrinking)	(2.39%)	(213.73%)
PBM Psyence Biomedical Ltd.	$16.5M	0.2×	—	—	n/m	−707.20% (below 0%: shrinking)	—	0.00%	Compare
TCRX TScan Therapeutics, Inc.	$16.2M	— (loss-making)	— (loss-making)	−65.83% (below 0%: shrinking)	n/m	+18.95% (above 0%: growing)	100.00%	(2,901.33%)	Compare
Median of peers	$17.4M	—	—	−78.29%	—	+12.76%	100.00%	0.00%

All 614 Biotechnology stocks →

Dyadic International Inc. (DYAI) key facts

Concern: Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.
Dyadic International Inc. (DYAI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DYAI traded at $0.41, a market capitalization of $16.8 million.
Return on equity was −397.8% and debt-to-equity -2.11.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −12.37 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.